Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial Results and Business Update Call.
Innate Pharma Sa (IPHA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 12,002 | $33,606 | -75% | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 46,888 | $131,286 | 0% | |
| 2. | 46,354 | $129,791 | 0% | |
| 3. | 22,705 | $63,574 | 0% | |
| 4. | 205 | $574 | 0% | |
| 5. | 200 | $560 | 0% |
News See All
Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Innate Pharma Third Quarter 2023 Financial Results and Business Update.
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your conference operator today.
Innate Pharma S.A. (NASDAQ:IPHA) Q3 2022 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Regina and I will be your conference operator today.
Is Innate Pharma S.A. (IPHA) A Good Stock To Buy?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.